8.7.2024 Evorpacept Combo Improves Responses in Pretreated HER2+ Gastric Cancer

Combination therapy with evorpacept (ALX148), trastuzumab (Herceptin), ramucirumab (Cyramza), and paclitaxel (TRP) meaningfully improved overall response rate (ORR) and duration of response (DOR) compared with TRP alone among those with previously treated HER2-positive advanced gastric cancer or gastroesophageal junction (GEJ) cancer, according to a press release on findings from the phase 2 ASPEN-06 trial (NCT05002127).1

Read More>

Posted in Uncategorized